Evaluation of the value of plasma concentration of copeptin in the first prenatal visit to diagnose gestational diabetes mellitus.
Gestational diabetes mellitus (GDM) is increasing worldwide. The aim of this study was to investigate whether copeptin concentrations, measured at the first prenatal visit, are associated with risk of GDM. From July 2015 to June 2016, consecutive women who admitted to the obstetrics center of our hospital were included. Data for fasting plasma glucose and copeptin concentrations at the first prenatal visit and one-step GDM screening with 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation were collected and analyzed. The relationship between levels of copeptin and GDM were evaluated using univariate and multivariate regression analysis. In this study, 101 out of the 827 women developed GDM (12.2%). The GDM distribution across the copeptin quartiles ranged between 4.4% (first quartile) and 25.1% (fourth quartile). For each 1 log-unit increase in plasma concentration of copeptin, the unadjusted and adjusted risk of GDM increased by 1442% (odds ratio 15.42 [95% CI 3.35-54.25], P < 0.001) and 642% (7.42 [2.69-16.02], P < 0.001), respectively. In a multivariate model using the fourth quartiles of copeptin versus quartiles 1 through 3 together with the clinical variables, the marker displayed prognostic information (GDM: OR for fourth quartile, 3.11 [95% CI 1.95-5.24; P = 0.001]). The net reclassification improvement statistic showed that the addition of copeptin to established risk factors significantly increased the correct reclassification of GDM (P = 0.02). The integrated discrimination improvement statistic found that the copeptin level significantly increased discrimination between women with GDM and without GDM (P = 0.01). High copeptin concentrations at the first prenatal visit were associated with increased risk of GDM and might be useful in identifying women at risk of GDM for early prevention strategies.